NEW YORK, April 14, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, notifies investors of class action against Rockwell Medical, Inc. ("Rockwell" or "the Company") (NASDAQ: RMTI). The class action has been filed in the United States District Court for the Southern District of New York on behalf of a class consisting of all persons or entities who purchased Rockwell securities between September 9, 2015 and February 29, 2016, both dates inclusive (the "Class Period").
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act").
The complaint alleges that Defendants violated federal securities laws by making false statements regarding and/or failing to disclose that the Company's main product offering for Triferic, an iron replacement drug, has not yet been approved by the FDA. On February 29, 2016, Rockwell announced its fourth quarter with disappointing results. Rockwell explained that it was still waiting for FDA approval of a powder packet form of Triferic, stopping its sale. Rockwell went on to explain that it was seeking to obtain transitional add-on payment reimbursement for Triferic with the Centers for Medicare & Medicaid Services instead of bundled reimbursement. Following this news, Rockwell stock dropped $3.29 or 34.27% to close at $6.31 on March 1, 2016.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint and join the action, visit the firm's website: http://www.bgandg.com/#!rmti/xqi5h. To discuss this action, or have any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Rockwell you have until May 3, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert---bronstein-gewirtz--grossman-llc-notifies-investors-of-class-action-against-rockwell-medical-inc-rmti-and-lead-plaintiff-deadline-may-3-2016-300251694.html
SOURCE Bronstein, Gewirtz & Grossman, LLC